Role of ventriculoperitoneal shunting in patients with neoplasms of the central nervous system: An analysis of 59 cases

Molecular and Clinical Oncology
Fares NigimEkkehard M Kasper

Abstract

Approximately 1-5% of patients with cerebral metastasis and ~40% of patients with primary brain tumors suffer from hydrocephalus. These patients often exhibit a poor prognosis. The aim of the present study was to reassess the validity of ventriculoperitoneal shunting (VPS) with the assistance of the general surgeon in oncological patients. A total of 59 patients underwent first-time VPS at the Beth Israel Deaconess Medical Center (Boston, USA) between 2004 and 2012; 40 patients had hydrocephalus from brain metastasis and 19 from primary tumors. The analyzed independent variables included demographics, body mass index, past medical history, clinical presentation, indication for surgery, Karnofsky performance status (KPS) score and surgical technique; the dependent variables were postoperative symptoms and occurrence, cause and time of shunt failure. The outcomes were analyzed with the t-test and Kaplan-Meier estimates for shunt survival. The mean age of the patients was 57.2 years and the mean operative time was 50.4 min. Symptomatic palliation was achieved in 93% of the cases; patients with severe symptoms, such as debilitating headaches, nausea and vomiting, benefited significantly from VPS. The mean follow-up time was 6.3 mon...Continue Reading

References

Aug 1, 1979·Neuropädiatrie·R W OberbauerH Becker
May 1, 1976·Journal of Neurosurgery·H J HoffmanR P Humphreys
Oct 1, 1985·Cancer·H J Hoffman, P K Duffner
May 1, 1971·Journal of Neurosurgery·T WakamatsuH Matsumura
Oct 1, 1980·AJR. American Journal of Roentgenology·P J Triolo, E E Schulz
Sep 1, 1981·Annals of Neurology·P K Duffner, M E Cohen
Oct 1, 1980·Journal of Neurosurgery·E D Rubery, T K Wheeler
Nov 2, 1994·Journal of the National Cancer Institute·P H PedersenR Bjerkvig
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J GlantzM J Egorin
Apr 25, 2000·Journal of Neuro-oncology·R MiralbellG Pizzolato
Mar 8, 2003·Acta Neuropathologica·Christian H Rickert
Dec 4, 2003·Clinical Neurology and Neurosurgery·Joji InamasuKiyoshi Ichikizaki
Sep 1, 2004·Journal of the Neurological Sciences·Ulrich HerrlingerMichael Weller
Dec 2, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·W BoogerdCh J Vecht
May 11, 2005·Neurology·Antonio M P OmuroLisa M DeAngelis
Jun 17, 2005·Expert Opinion on Pharmacotherapy·George Pentheroudakis, Nicholas Pavlidis
Dec 14, 2005·Journal of Neuro-oncology·Andrew B LassmanJeffrey J Raizer
Sep 22, 2006·Current Opinion in Oncology·Sophie Taillibert, Jerzy Hildebrand
Oct 27, 2007·Gynecologic Oncology·Yesim EralpErkan Topuz
Oct 4, 2008·Journal of Neurosurgery. Pediatrics·Michael H Handler, Brian Callahan
Dec 17, 2008·Clinical Radiology·K LobotesisN M Antoun
Mar 19, 2009·Journal of Neurology, Neurosurgery, and Psychiatry·D FarahmandM Tisell
Mar 31, 2009·Journal of Palliative Medicine·Deborah SchiffJoAnne Auger
Dec 21, 2010·Seminars in Cancer Biology·Isaiah J Fidler
Jan 29, 2011·Journal of Neuro-oncology·Seung Hoon LeeJung-Il Lee

❮ Previous
Next ❯

Citations

Sep 9, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Le RhunUNKNOWN EANO Executive Board and ESMO Guidelines Committee
Nov 2, 2018·Nursing·Vincent M Vacca
Nov 3, 2016·Current Opinion in Neurology·Emilie Le Rhun, Evanthia Galanis
Jun 12, 2020·International Medical Case Reports Journal·Shimpei SugaokaMasaru Takeuchi
May 23, 2019·Cambridge Quarterly of Healthcare Ethics : CQ : the International Journal of Healthcare Ethics Committees·Daniel P Sulmasy, Mariele A Courtois
Dec 5, 2020·Continuum : Lifelong Learning in Neurology·Adrienne Boire
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Le RhunUNKNOWN EANO Executive Board and ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Aug 24, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Philipp KarschniaJoerg-Christian Tonn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.